ValuEngine upgraded shares of Avenue Therapeutics (NASDAQ:ATXI) from a hold rating to a buy rating in a research report report published on Thursday.
Several other research analysts have also recently weighed in on ATXI. Oppenheimer started coverage on shares of Avenue Therapeutics in a report on Thursday, July 12th. They set a buy rating and a $8.00 price target on the stock. HC Wainwright restated a buy rating and set a $11.00 price target on shares of Avenue Therapeutics in a report on Wednesday, August 15th.
Shares of NASDAQ:ATXI traded up $0.12 during midday trading on Thursday, hitting $3.67. 8,000 shares of the company’s stock were exchanged, compared to its average volume of 40,216. Avenue Therapeutics has a 12 month low of $2.08 and a 12 month high of $5.90. The company has a market cap of $36.62 million, a PE ratio of -2.07 and a beta of -1.21.
Avenue Therapeutics (NASDAQ:ATXI) last released its quarterly earnings results on Tuesday, August 14th. The company reported ($0.45) earnings per share for the quarter, topping the consensus estimate of ($0.68) by $0.23. As a group, equities research analysts predict that Avenue Therapeutics will post -2.14 earnings per share for the current year.
About Avenue Therapeutics
Avenue Therapeutics, Inc, a specialty pharmaceutical company, acquires, licenses, develops, and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, which is in Phase III clinical trials to treat moderate to moderately severe post-operative pain.
Recommended Story: How do investors use RSI to grade stocks?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Avenue Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avenue Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.